Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial

Bajpai et al., medRxiv, doi:10.1101/2020.10.25.20219337 (Preprint)

Bajpai et al., Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A.., medRxiv, doi:10.1101/2020.10.25.20219337 (Preprint)

Oct 2020 Source PDF

Twitter
Facebook

All Studies Meta

Small RCT 29 patients in India, 14 treated with convalescent plasma, not showing significant differences with treatment.

Important missing comments or errors? Let us know.

risk of death, 323.0% higher, HR 4.23, p = 0.22, treatment 3 of 14 (21.4%), control 1 of 15 (6.7%), adjusted per study, 28 days, Cox proportional hazards.

risk of death, 114.3% higher, RR 2.14, p = 0.60, treatment 2 of 14 (14.3%), control 1 of 15 (6.7%), 7 days.

risk of mechanical ventilation, 221.4% higher, RR 3.21, p = 0.33, treatment 3 of 14 (21.4%), control 1 of 15 (6.7%), 7 days.

hospitalization time, 24.8% lower, relative time 0.75, p = 0.08, treatment 14, control 15.

relative improvement in Ct value, 32.5% better, RR 0.68, p = 0.11, treatment 14, control 15.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Bajpai et al., 27 Oct 2020, Randomized Controlled Trial, India, preprint, 20 authors.

All Studies All Outcomes Submit Updates or Corrections

This Paper Conv. Plasma All

Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial

Dr Meenu Bajpai, Dr Suresh Kumar, Dr Ashish Maheshwari, Dr Karan Chhabra, Pratibha Kale, Dr Amita Gupta, Dr Ashad Narayanan, Dr Ekta Gupta, Dr Nirupama Trehanpati, Dr Chhagan Bihari, Dr Reshu Agarwal, Kamini Gupta, Upendra Kumar Gupta, Dr Ankit Bhardwaj, Dr Guresh Kumar, M.Sc Mojahidul Islam, Ravinder Singh, M.Sc Pushpa Yadav, Dr Rakhi Maiwall, Dr Shiv Kumar Sarin

doi:10.1101/2020.10.25.20219337

Conflict of Interest: None declared. Acknowledgements: We thank Mr Pankaj Jain for his technical support in the trial.

References

Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med

Chen, Xiong, Bao, Shi, Convalescent plasma as a potential therapy for COVID-19, Lancet Infect Dis

Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet

De Brito, Lucena-Silva, Torres, Luna, Correia et al., The

Duan, Liu, Li, Zhang, Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A

Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med

Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med

Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet

Joyner, Wright, Fairweather, Senefeld, Bruno et al., Early safety indicators of COVID-19 convalescent plasma in 5000 patients, J Clin Invest

Li, Zhang, Hu, Tong, Zheng et al., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial, JAMA

Ng, Oong, Lim, Chook, Takebe et al., Viral Load and Sequence Analysis Reveal the Symptom Severity, Diversity, and Transmission Clusters of Rhinovirus Infections, Clin Infect Dis

Shen, Wang, Zhao, Yang, Li et al., Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma, JAMA

Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA

Zhang, Liu, Tan, Huang, Dong et al., Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Chest

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit